tirzepatide for the treatment of obstructive sleep apnea and obesity Eli Lilly's gained FDA approval in December 2024 treating moderate-to-severe in adults with obesity, after Phase III trials showed a 20% average weight loss a roughly Clinical Impact of Tirzepatide on

A study published in Canadian Health Policys October 2024 issue confirmed previous analysis that determined that U.S

Among the effects of this class of drugs, slowing gastric emptying is the most notable concern for anaes thetists because of its potential increased risk of gastric regurgitation and subsequent pulmonary aspiration during induction of general anaesthesia

Rather than directly activating GABA-A receptors, the peptide appears to maintain homeostasis of the entire GABA receptor complex, preventing the desensitization and compensatory changes that produce tolerance and dependence

These documents explain the basis for coverage decisions

It should only be used within the context of authorised clinical trials

Build meals that keep you full What you eat still matters, even on a maintenance dose